Literature DB >> 18834416

Tumor cell dormancy: implications for the biology and treatment of breast cancer.

T Fehm1, V Mueller, R Marches, G Klein, B Gueckel, H Neubauer, E Solomayer, S Becker.   

Abstract

Despite progress made in the therapy of solid tumors such as breast cancer, the prognosis of patients even with small primary tumors is still limited by metastatic relapse often long after removal of the primary tumor. Therefore, it has been hypothesized that primary tumors shed tumor cells already at an early stage into the blood circulation. A subset of these disseminated tumor cells may persist in a state of so-called "dormancy". Based on cell culture and animal models, dormancy can occur at two different stages. Single dormant cells are defined as cells with a lack of proliferation and apoptosis with the cells undergoing cell cycle arrest. The micrometastasis model defines tumor cell dormancy as a state of balanced apoptosis and proliferation of micrometastasis resulting in no net increase of tumor mass. Mechanisms leading to a growth activation of dormant tumor cells and the outgrowth of manifest metastases are not completely understood. Genetic predisposition of the dormant cells as well as immunological and angiogenetic influences of the surrounding environment may contribute to this phenomenon. In this review, we summarize findings on different factors for tumor cell dormancy and potential therapeutic implications that should help to reduce metastatic relapse in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18834416     DOI: 10.1111/j.1600-0463.2008.01047.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  15 in total

Review 1.  Circulating Tumor Cells in Early-Stage Breast Cancer.

Authors:  A D Hartkopf; M Banys; N Krawczyk; M Wallwiener; H Schneck; H Neubauer; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

2.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 3.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

4.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Authors:  Xin Lu; Euphemia Mu; Yong Wei; Sabine Riethdorf; Qifeng Yang; Min Yuan; Jun Yan; Yuling Hua; Benjamin J Tiede; Xuemin Lu; Bruce G Haffty; Klaus Pantel; Joan Massagué; Yibin Kang
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

5.  Autophagy regulation in cancer development and therapy.

Authors:  Erin J White; Vanesa Martin; Juinn-Lin Liu; Sarah R Klein; Sujan Piya; Candelaria Gomez-Manzano; Juan Fueyo; Hong Jiang
Journal:  Am J Cancer Res       Date:  2010-01-25       Impact factor: 6.166

Review 6.  Dormancy in breast cancer.

Authors:  Malgorzata Banys; Andreas D Hartkopf; Natalia Krawczyk; Tatjana Kaiser; Franziska Meier-Stiegen; Tanja Fehm; Hans Neubauer
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-12-05

7.  Comparing the fate of brain metastatic breast cancer cells in different immune compromised mice with cellular magnetic resonance imaging.

Authors:  Natasha N Knier; Amanda M Hamilton; Paula J Foster
Journal:  Clin Exp Metastasis       Date:  2020-06-12       Impact factor: 5.150

8.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Authors:  Bradley N Bidwell; Clare Y Slaney; Nimali P Withana; Sam Forster; Yuan Cao; Sherene Loi; Daniel Andrews; Thomas Mikeska; Niamh E Mangan; Shamith A Samarajiwa; Nicole A de Weerd; Jodee Gould; Pedram Argani; Andreas Möller; Mark J Smyth; Robin L Anderson; Paul J Hertzog; Belinda S Parker
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

9.  Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice.

Authors:  Qing Sun; Yong Zhong; Fan Wu; Chunxia Zhou; Dongmei Wang; Wenbo Ma; Youhui Zhang; Shuren Zhang
Journal:  BMC Med       Date:  2012-12-27       Impact factor: 8.775

10.  The role of autophagy in tumour development and cancer therapy.

Authors:  Mathias T Rosenfeldt; Kevin M Ryan
Journal:  Expert Rev Mol Med       Date:  2009-12-02       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.